INDO US BIOTECH
Back to Balance Sheet
|
INDO US BIOTECH Last 5 Year Total Current Liabilities History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹16 Cr | ₹17 Cr | ₹12 Cr | ₹12 Cr | ₹18 Cr |
What is the latest Total Current Liabilities ratio of INDO US BIOTECH ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹16 Cr |
| Mar2024 | ₹17 Cr |
| Mar2023 | ₹12 Cr |
| Mar2022 | ₹12 Cr |
| Mar2021 | ₹18 Cr |
How is Total Current Liabilities of INDO US BIOTECH Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹16 Cr | -6.44 | |
| Mar2024 | ₹17 Cr | 42.06 | |
| Mar2023 | ₹12 Cr | 0.70 | |
| Mar2022 | ₹12 Cr | -32.03 | |
| Mar2021 | ₹18 Cr | - | |
Compare Total Current Liabilities of peers of INDO US BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDO US BIOTECH | ₹207.4 Cr | 4.1% | -28.5% | -39.1% | Stock Analytics | |
| BOMBAY BURMAH TRADING CORPORATION | ₹10,547.1 Cr | -0.8% | -16.4% | -6.4% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹3,940.5 Cr | -5.5% | -9.1% | -26.5% | Stock Analytics | |
| VENKYS (INDIA) | ₹1,750.6 Cr | 2.4% | -12.5% | -17.2% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹829.0 Cr | -3.7% | -14.1% | -37.3% | Stock Analytics | |
| MANGALAM GLOBAL ENTERPRISE | ₹334.5 Cr | -0.6% | -14.9% | -29.6% | Stock Analytics | |
INDO US BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDO US BIOTECH | 4.1% |
-28.5% |
-39.1% |
| SENSEX | -2.4% |
-10.9% |
0.2% |
You may also like the below Video Courses